© sdecoret iStockphoto

Cutaneous T-cell lymphoma

Mogamulizumab superior to vorinostat for previously treated CTCL

<p class="article-intro">Youn H. Kim, MD, of Stanford University, talking about the results from the phase-III-study MAVORIC.</p> <hr /> <p class="article-content"><p><iframe src="https://player.vimeo.com/video/246953314" width="640" height="360" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p></p>
Back to top